| Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ... New england journal of medicine 375 (23), 2246-2254, 2016 | 790 | 2016 |
| Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer CN Sternberg, K Fizazi, F Saad, ND Shore, U De Giorgi, DF Penson, ... New England Journal of Medicine 382 (23), 2197-2206, 2020 | 363 | 2020 |
| Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study S Faivre, E Raymond, E Boucher, J Douillard, HY Lim, JS Kim, M Zappa, ... The lancet oncology 10 (8), 794-800, 2009 | 346 | 2009 |
| Body mass index and metastatic renal cell carcinoma: clinical and biological correlations L Albiges, AA Hakimi, W Xie, RR McKay, R Simantov, X Lin, JL Lee, ... Journal of Clinical Oncology 34 (30), 3655, 2016 | 220 | 2016 |
| Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results RJ Motzer, A Ravaud, JJ Patard, HS Pandha, DJ George, A Patel, ... European urology 73 (1), 62-68, 2018 | 215 | 2018 |
| Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy AJ Templeton, JJ Knox, X Lin, R Simantov, W Xie, N Lawrence, R Broom, ... European urology 70 (2), 358-364, 2016 | 167 | 2016 |
| Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, ... Journal of Clinical Oncology 31 (10), 1341-1347, 2013 | 150 | 2013 |
| Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma RJ Motzer, B Escudier, R Bukowski, BI Rini, TE Hutson, CH Barrios, X Lin, ... British journal of cancer 108 (12), 2470-2477, 2013 | 146 | 2013 |
| Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma RR McKay, GE Rodriguez, X Lin, MD Kaymakcalan, OPR Hamnvik, ... Clinical Cancer Research 21 (11), 2471-2479, 2015 | 134 | 2015 |
| Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials AM Molina, X Lin, B Korytowsky, E Matczak, MJ Lechuga, R Wiltshire, ... European journal of cancer 50 (2), 351-358, 2014 | 133 | 2014 |
| Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial N Agarwal, AA Azad, J Carles, AP Fay, N Matsubara, D Heinrich, ... The Lancet 402 (10398), 291-303, 2023 | 121 | 2023 |
| Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients F Donskov, MD Michaelson, I Puzanov, MP Davis, GA Bjarnason, ... British journal of cancer 113 (11), 1571-1580, 2015 | 111 | 2015 |
| Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib S Faivre, M Zappa, V Vilgrain, E Boucher, JY Douillard, HY Lim, JS Kim, ... Clinical Cancer Research 17 (13), 4504-4512, 2011 | 93 | 2011 |
| Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma TE Hutson, RM Bukowski, BI Rini, ME Gore, JM Larkin, RA Figlin, ... British journal of cancer 110 (5), 1125-1132, 2014 | 83 | 2014 |
| Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma RR McKay, X Lin, JJ Perkins, DYC Heng, R Simantov, TK Choueiri European urology 66 (3), 502-509, 2014 | 76 | 2014 |
| Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma V Grünwald, RR McKay, KM Krajewski, D Kalanovic, X Lin, JJ Perkins, ... European urology 67 (5), 952-958, 2015 | 74 | 2015 |
| Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma AKA Lalani, W Xie, DA Braun, M Kaymakcalan, D Bossé, JA Steinharter, ... European urology oncology 3 (3), 372-381, 2020 | 69 | 2020 |
| Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib BI Rini, B Escudier, JF Martini, A Magheli, C Svedman, M Lopatin, ... Clinical Cancer Research 24 (18), 4407-4415, 2018 | 53 | 2018 |
| Statins and survival outcomes in patients with metastatic renal cell carcinoma RR McKay, X Lin, L Albiges, AP Fay, MD Kaymakcalan, SS Mickey, ... European Journal of Cancer 52, 155-162, 2016 | 53 | 2016 |
| Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial M Staehler, RJ Motzer, DJ George, HS Pandha, F Donskov, B Escudier, ... Annals of Oncology 29 (10), 2098-2104, 2018 | 49 | 2018 |
